Publications by authors named "J Voortman"
Background: Addition of neoadjuvant immune checkpoint inhibition to standard-of-care interventions for locally advanced oral cancer could improve clinical outcome.
Methods: In this study, 16 evaluable patients with stage III/IV oral cancer were treated with one dose of 480 mg nivolumab 3 weeks prior to surgery. Primary objectives were safety, feasibility, and suitability of programmed death receptor ligand-1 positron emission tomography (PD-L1 PET) as a biomarker for response.
Article Synopsis
- Immune checkpoint inhibitors (ICI) enhance survival in metastatic urothelial cancer (mUC) patients, but response varies greatly among individuals.
- Researchers analyzed DNA and RNA from tumors to find predictive markers for treatment response, discovering that tumor mutational burden and T cell-to-stroma enrichment (TSE) score are key indicators.
- The TSE score is highly accurate in predicting which patients will respond to ICI treatment and could be used to select patients for therapy in clinical settings.
Article Synopsis
- Chemoradiotherapy using a triweekly cisplatin regimen of 100 mg/m² is employed to treat locally advanced head and neck squamous cell carcinoma (HNSCC), but often leads to dose limiting toxicity (CDLT) that can compromise treatment effectiveness.
- Patients with low skeletal muscle mass (SMM) face a significantly higher risk of CDLT, prompting the use of routine diagnostic scans to assess SMM.
- A multicenter randomized clinical trial is exploring whether switching to a weekly cisplatin regimen of 40 mg/m² improves treatment compliance among patients with low SMM by reducing CDLT while allowing for a higher cumulative dose.